Brand Name | Status | Last Update |
---|---|---|
alvaiz | New Drug Application | 2024-07-01 |
eltrombopag | ANDA | 2025-09-03 |
promacta | New Drug Application | 2025-08-18 |
Expiration | Code | ||
---|---|---|---|
ELTROMBOPAG OLAMINE, PROMACTA, NOVARTIS | |||
2025-11-16 | ODE-210 | ||
ELTROMBOPAG OLAMINE, PROMACTA KIT, NOVARTIS | |||
2025-11-16 | ODE* |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Eltrombopag Olamine, Promacta, Novartis | |||
8052993 | 2027-08-01 | DP | U-930, U-1306, U-1575, U-1714, U-2451 |
8052994 | 2027-08-01 | DP | U-930, U-1306, U-1714, U-2451 |
8062665 | 2027-08-01 | DP | U-930, U-1306, U-1714, U-2451 |
8071129 | 2027-08-01 | DP | U-930, U-1306, U-1714, U-2451 |
8828430 | 2027-08-01 | DP | U-1306, U-2451 |
7547719 | 2025-07-13 | DS, DP | U-930, U-1306, U-1575, U-1736, U-2451, U-2452 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Thrombocytopenia | D013921 | HP_0001873 | D69.6 | 11 | 42 | 11 | 10 | 18 | 85 |
Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | 8 | 20 | 15 | 10 | 19 | 70 |
Purpura | D011693 | HP_0000979 | D69.2 | 5 | 8 | 8 | 2 | 8 | 31 |
Thrombocytopenic purpura | D011696 | — | — | 4 | 8 | 8 | 2 | 7 | 29 |
Aplastic anemia | D000741 | — | D61.9 | 2 | 15 | 4 | 2 | 5 | 25 |
Healthy volunteers/patients | — | — | — | 3 | — | 1 | 1 | — | 5 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | 1 | 1 | 1 | 4 |
Hematologic neoplasms | D019337 | — | — | — | 1 | — | 1 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Anemia | D000740 | EFO_0004272 | D64.9 | 3 | 17 | 2 | — | 3 | 21 |
Leukemia | D007938 | — | C95 | 5 | 15 | 2 | — | — | 17 |
Myelodysplastic syndromes | D009190 | — | D46 | 3 | 11 | 1 | — | 1 | 16 |
Preleukemia | D011289 | — | — | 3 | 10 | 1 | — | — | 14 |
Syndrome | D013577 | — | — | 3 | 9 | 1 | — | — | 13 |
Myeloid leukemia acute | D015470 | — | C92.0 | 4 | 9 | 1 | — | — | 11 |
Hepatitis c | D006526 | — | B19.2 | 1 | 3 | 6 | — | 2 | 11 |
Myeloid leukemia | D007951 | — | C92 | 4 | 8 | 2 | — | — | 10 |
Hepatitis | D006505 | — | K75.9 | — | 3 | 5 | — | 1 | 8 |
Hepatitis a | D006506 | EFO_0007305 | B15 | — | 3 | 5 | — | — | 7 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Blood platelet disorders | D001791 | — | — | — | 3 | — | — | 1 | 4 |
Pancytopenia | D010198 | — | D61.81 | 1 | 3 | — | — | — | 3 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | 3 | — | — | — | 3 |
Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | — | 1 | — | — | 1 | 2 |
Wiskott-aldrich syndrome | D014923 | EFO_0003903 | D82.0 | — | 2 | — | — | — | 2 |
Fanconi anemia | D005199 | Orphanet_84 | D61.03 | — | 2 | — | — | — | 2 |
Fanconi syndrome | D005198 | — | — | — | 2 | — | — | — | 2 |
Megakaryoblastic leukemia acute | D007947 | — | C94.2 | 1 | 1 | — | — | — | 2 |
Monocytic leukemia acute | D007948 | — | — | 1 | 1 | — | — | — | 2 |
Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Sarcoma | D012509 | — | — | 2 | — | — | — | — | 2 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | — | — | — | — | 1 |
Osteosarcoma | D012516 | — | — | 1 | — | — | — | — | 1 |
Connective and soft tissue neoplasms | D018204 | — | — | 1 | — | — | — | — | 1 |
Radiation injuries | D011832 | — | T66 | 1 | — | — | — | — | 1 |
Acute radiation syndrome | D054508 | — | — | 1 | — | — | — | — | 1 |
Photosensitivity disorders | D010787 | — | L57.1 | 1 | — | — | — | — | 1 |
Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Splenectomy | D013156 | — | — | — | — | — | — | 1 | 1 |
Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
Immune system diseases | D007154 | — | D89.9 | — | — | — | — | 1 | 1 |
Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | — | 1 | 1 |
Hemorrhagic disorders | D006474 | — | D69.9 | — | — | — | — | 1 | 1 |
Skin manifestations | D012877 | — | — | — | — | — | — | 1 | 1 |
Thromboembolism | D013923 | — | — | — | — | — | — | 1 | 1 |
Thalassemia | D013789 | EFO_1001996 | D56 | — | — | — | — | 1 | 1 |
Bone marrow diseases | D001855 | — | — | — | — | — | — | 1 | 1 |
Paroxysmal hemoglobinuria | D006457 | Orphanet_447 | D59.12 | — | — | — | — | 1 | 1 |
Drug common name | Eltrombopag |
INN | eltrombopag |
Description | Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. Eltrombopag is sold under the brand name Revolade outside the US and is marketed by Novartis. It is a thrombopoietin receptor agonist. It is taken by mouth.
|
Classification | Small molecule |
Drug class | thrombopoetin agonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O |
PDB | — |
CAS-ID | 496775-61-2 |
RxCUI | — |
ChEMBL ID | CHEMBL461101 |
ChEBI ID | 85010 |
PubChem CID | 9846180 |
DrugBank | DB06210 |
UNII ID | S56D65XJ9G (ChemIDplus, GSRS) |